TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05598710

Intervention type: PROCEDURE
Intervention: Pigtail Insertion
Description: Pigtail is inserted for any reason of ureteral obstruction except for malignant

Intervention type: PROCEDURE
Intervention: Pigtail Insertion
Description: Pigtail is inserted for any reason of ureteral obstruction except for malignant

Intervention type: PROCEDURE
Intervention: Pigtail Insertion
Description: Pigtail is inserted for any reason of ureteral obstruction except for malignant

Intervention type: PROCEDURE
Intervention: Pigtail Insertion
Description: Pigtail is inserted for any reason of ureteral obstruction except for malignant
Study: NCT06464926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra Therapy System
Description: The Enterra Therapy System is a gastric electrical stimulator system consisting of an implantable pulse generator (Enterra II Model 37800 neurostimulator); two implantable unipolar leads (Enterra Model 4351-35 intramuscular); and device programmer (N'Vision Clinician Programmer Model 8840 with Model 8870 Application Card).~The programmable neurostimulator operates on a sealed battery and electronic circuitry to provide controlled electrical pulse stimulation through the implanted lead system. A clinician programmer is used to program the neurostimulator and adjust stimulation settings to programmable parameters and stimulation options.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra Therapy System
Description: The Enterra Therapy System is a gastric electrical stimulator system consisting of an implantable pulse generator (Enterra II Model 37800 neurostimulator); two implantable unipolar leads (Enterra Model 4351-35 intramuscular); and device programmer (N'Vision Clinician Programmer Model 8840 with Model 8870 Application Card).~The programmable neurostimulator operates on a sealed battery and electronic circuitry to provide controlled electrical pulse stimulation through the implanted lead system. A clinician programmer is used to program the neurostimulator and adjust stimulation settings to programmable parameters and stimulation options.
Study: NCT06665971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Description: Dosage form: Subcutaneous injection Dosage: 300 mg/ 2ml Dosage frequency: Once a week Duration: 12 weeks
Study: NCT04847102

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SARS-CoV-2 mRNA Vaccine
Description: The SARS-CoV-2 mRNA Vaccine is formulated by encapsulating the mRNA, which encodes the receptor-binding domain (RBD) of spike glycoprotein (S protein) of SARS-CoV-2 and is transcribed in-vitro by the corresponding DNA template, in lipid nanoparticles (LNPs). This vaccine is presented as a white to off-white dispersion for injection.~Active substances: mRNA encoding the RBD of the S protein of SARS-CoV-2.~The vaccine is supplied in single-dose pre-filled syringe with 0.5 mL dispersion for intramuscular injection. Each dose (0.5 mL) of the vaccine contains:~15 μg of mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2, 0.339 mg of total lipids (including lipid 9001, cholesterol, DSPC, DMG-PEG2000).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA Vaccine
Description: The SARS-CoV-2 mRNA Vaccine is formulated by encapsulating the mRNA, which encodes the receptor-binding domain (RBD) of spike glycoprotein (S protein) of SARS-CoV-2 and is transcribed in-vitro by the corresponding DNA template, in lipid nanoparticles (LNPs). This vaccine is presented as a white to off-white dispersion for injection.~Active substances: mRNA encoding the RBD of the S protein of SARS-CoV-2.~The vaccine is supplied in single-dose pre-filled syringe with 0.5 mL dispersion for intramuscular injection. Each dose (0.5 mL) of the vaccine contains:~15 μg of mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2, 0.339 mg of total lipids (including lipid 9001, cholesterol, DSPC, DMG-PEG2000).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride solution, 0.5 mL/vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride solution, 0.5 mL/vial
Study: NCT05947227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko breathing technique
Description: Group A : will be treated with manual chest physiotherapy \& Buteyko Breathing exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing technique.
Description: Group B : will be treated with manual chest physiotherapy \& Diaphragmatic Breathing Treatment evaluation will be done after 8 weeks through 6MWT \& St George respiratory Questionnaire. Patients will perform technique 5 times a weeks for 8 weeks
Study: NCT06710899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine Hippurate 1g BD
Description: Methenamine Hippurate 1g BD for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine Hippurate 1g BD
Description: Methenamine Hippurate 1g BD for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine Hippurate 1g BD + Vitamin C 1g BD
Description: Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months
Study: NCT06718036

Intervention type: OTHER
Intervention: Validation and evaluation of the use of the ICF Rehabilitation Set in clinical practice
Description: Validation and evaluation of the use of the ICF Rehabilitation Set in clinical practice
Study: NCT06717854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transanal irrigation
Description: The enema is administered retrogradely via the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antegrade enema
Description: The enema is administered through the distal end of the ileocecal stoma, directed towards the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.
Study: NCT06725667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversalis fascia plane block
Description: Patients will receive transversalis fascia plane block after the induction of general anesthesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Patients will receive caudal block after the induction of general anesthesia.
Study: NCT06731439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starting feeds within 6 hours of life
Description: Starting feeds within 6 hours of life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard feeding protocol
Description: Starting feeds based on standard protocol as per primary team
Study: NCT06731634

Intervention type: DEVICE
Intervention: Hand grip strength dynamometer, pinch strength dynamometer
Description: Both devices will be used to assign the strength of grip and pinch for both dominant and non dominant hands by using jamar hydraulic hand grip strength dynamometer and Jamar hydraulic pinch strength dynamometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Finkelstein test
Description: Finkelstein test which is used to diagnose the de quervain tenosynovitis and it will be used to assist the people with smartphone addiction
Study: NCT06731400

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA supplementation
Description: Six healthy individuals will be supplemented with fish oil contains omega 3 (EPA) for eight weeks, with blood samples collected before and after the intervention.
Study: NCT06730581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Capsule 60mg/m2/d
Description: 60mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone capsule 75mg/m2
Description: 75mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
Study: NCT05892835

Intervention type: OTHER
Group type: OTHER
Intervention: Educative
Description: A 2-hour training workshop was held where a theoretical explanation was given to recognize a cardiorespiratory arrest, the correct technique of chest compressions, ventilations and DESA management, in addition a practical class was carried out with CPR training models (Manikin for CPR practices Little Anne QCPR). Laerdal and AED simulation for CPR training (AED Practi-Trainer - Bilingual. WNL). Both theoretical and practical training were given by a basic life support instructor from the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC), the participants were instructed under the guidelines of the 2021 CKD recommendations.
Study: NCT05390138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Sleep Apnea Self-management Support Programme (4S)
Description: The experimental group will receive usual care and Smart Sleep Apnea Self-management Support Programme (4S). The 4S includes two interview sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to self-management. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Hygiene Information (GH)
Description: The control group will receive usual care and general hygiene information (GH). The GH includes two GH sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to general hygiene information. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
Study: NCT06381037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How to improve your strengths and quality of life.
Description: The intervention program How to improve your strengths and quality of life consists of 8 individual sessions. The sessions take place weekly, so the total duration of the program is 8 weeks. Each session lasts approximately 1 hour. The sessions will be held both in person and online.~The sessions are:~* Session 1: Introduction to quality of life and personal strengths.~* Session 2: Self-fulfillment.~* Session 3: Pleasure.~* Session 4: Autonomy and control.~* Session 5: Family functioning and assertive communication.~* Session 6: Resilience.~* Session 7: Experiential acceptance.~* Session 8: Gratitude and closing of the workshop.
Study: NCT06730581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Capsule
Description: Dosing regimens were determined based on the results of gastric and ovarian cancer dosing regimens.D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
Study: NCT06731621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 2 dosing sessions 1 week apart, each about 6-8 hours duration~Psilocybin-assisted therapy (PAT), is a psychotherapeutic intervention in which the psychological effects of psilocybin play a significant role. PAT procedures typically involve psychological preparation prior to therapist-supported psilocybin dosing sessions. These sessions are used to establish a therapeutic relationship, inform participants about what to expect, and set expectations for the dosing session. During the psilocybin dosing session, trained therapists support the individual through their experience and psychological integration therapy occurs after the dosing experience. PAT has shown impressive antidepressant effects in people with TRD or severe MDD in at least six modern-era clinical trials (Andersen et al., 2021).
Study: NCT06731309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Debridement
Description: A punch biopsy tool is positioned over the inflamed follicular unit, and a small circle of skin (4 to 8 mm in diameter) is excised. A firm twisting motion is necessary to ensure adequately deep excision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage
Description: Incision and Drainage is a minimally invasive surgical procedure often employed for the treatment of intensely painful, tense, and fluctuant abscesses that are too deep to drain spontaneously. After administration of a broad circumferential local anesthetic, a small linear incision is made using a standard scalpel blade. Digital pressure is applied to expel the fluid collection. Saline rinses can be used to flush out the remaining contents. This method offers instant pain relief, commonly performed in acute settings by dermatologists, emergency department physicians and general practitioners
Study: NCT06731075

Intervention type: DRUG
Group type: OTHER
Intervention: ORMD-0801 8 mg
Description: 1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).

Intervention type: DRUG
Group type: OTHER
Intervention: ORMD-0801 8 mg
Description: 1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo capsule
Description: Placebo capsule

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo capsule
Description: Placebo capsule

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo capsule
Description: Placebo capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule

Intervention type: DRUG
Group type: OTHER
Intervention: ORMD-0801 16 mg
Description: 2 x 8 mg capsules between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 1 placebo capsule in the morning.
Study: NCT06731348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: restricted opioid prescribing
Description: Participants in the restricted opioid prescribing group will receive restricted opioid prescribing after surgery. They will receive 1 tablet of Oxycodone HCl 5mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard opioid prescribing
Description: Participants will receive standard opioid prescribing - Oxycodone HCl 5mg x10 tablets for major cases, 5 tablets for minor cases.
Study: NCT06731790

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling for inflammatory phenotype analysis
Description: Blood sampling for basal and post-stimulation inflammatory phenotype analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling for inflammatory phenotype analysis
Description: Blood sampling for basal and post-stimulation inflammatory phenotype analysis

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling for genetic analysis
Description: Collection of a blood tube for whole exome sequencing of the RANBP2 gene and analysis of the presence of the mutation by RTqPCR.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sampling for genetic analysis
Description: Collection of a blood tube for whole exome sequencing of the RANBP2 gene and analysis of the presence of the mutation by RTqPCR.
Study: NCT05342428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablets
Description: Oral tablets administered at different doses BID daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablets
Description: Oral tablets administered at different doses BID daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablets
Description: Oral tablets administered at different doses BID daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TLL018 tablets
Description: Oral tablets administered at different doses BID daily for 12 weeks.
Study: NCT05428384

Intervention type: DEVICE
Intervention: MRI/ CardioMEMS comparison
Description: Each subject will have CardioMEMS readings paired with MRI scans
Study: NCT03943927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Metoprolol Management
Description: CYP2D6 Genotyping: Consented patients will have blood drawn for genotyping prior to surgery. Patients will be classified as poor metabolizers, intermediate metabolizers, extensive (normal) metabolizers, or ultrafast metabolizers.~Pharmacogenetic- Guided Metoprolol Management: A best practice advisory will be integrated into institutional clinical decision support systems for metoprolol dosing based on metabolic status of each patient.
Study: NCT05008809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Folinic acid: 400mg/m², 1-2h IV Infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Irinotecan: 180 mg/m², 90-120 min IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: Capecitabine: 1000 mg/m², oral 1-0-1 on d1-14 Oxaliplatin: 130 mg/m², 3h IV infusion on d1 Cycles are repeated on day 22. A total of up to 8 cycles isadministered.
Study: NCT05409430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurothrombectomy
Description: The ANA 5F device is intended to be inserted, be navigated to the neurovascular anatomy inside an outer catheter and be used as a conduit for insertion and guidance of intravascular catheters and retrieval devices into a selected blood vessel. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction.~The device is indicated for the introduction of interventional devices into the neuro vasculature, during interventions for restoring blood flow in patients experiencing acute ischemic stroke due to large vessel occlusion.
Study: NCT05677815

Intervention type: PROCEDURE
Intervention: Underwent Surgery from 2019 to 2022
Description: Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional, or local anaesthesia

Intervention type: PROCEDURE
Intervention: Underwent Surgery from 2019 to 2022
Description: Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional, or local anaesthesia
Study: NCT04878458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy
Description: The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification with intraocular lens implantation combined with trabeculectomy
Description: The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.
Study: NCT05843240

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: After enrollment, patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: After enrollment, patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
Study: NCT06523439

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagPro X100 edition (MagVenture, Skovlunde, Denmark)
Description: 10 daily sessions (50 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100 edition (MagVenture, Skovlunde, Denmark)
Description: 5 daily sessions (25 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
Study: NCT06446349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Description: identification followed by a brief motivational intervention in pharmacies (BMI) based on the mobilisation of patients' psychosocial skills and the integration of tools to help reduce consumption of BZD/Z prescribed over the long term (≥ 6 months).
Study: NCT05262868

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: The stimulus intensity will be 80% of the motor threshold and the frequency will be 20 Hz for all patients. The total number of pulses will be 1200 for a single treatment session. We plan a total of 15 sessions distributed over 5 days a week for 3 consecutive weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS
Description: The stimulus intensity will be 80% of the motor threshold and the frequency will be 20 Hz for all patients. The total number of pulses will be 1200 for a single treatment session. We plan a total of 15 sessions distributed over 5 days a week for 3 consecutive weeks.
Study: NCT05961345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: late mobilization
Description: Early mobilization of patients after surgery is supported. The relationship between early mobilization and pain level was examined. The experimental group is 80 people.